Obiara 120 Capsule contains Orlistat 120 mg, a potent lipase inhibitor indicated for the management of obesity. Orlistat acts locally in the gastrointestinal tract by selectively inhibiting pancreatic and gastric lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of ingested fat, Obiara 120 facilitates weight reduction in conjunction with a reduced-calorie diet. It is prescribed for adults with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or higher who present with obesity-related risk factors such as hypertension, type 2 diabetes, or dyslipidemia. Clinical studies have demonstrated that Orlistat, when combined with lifestyle modifications including diet and exercise, significantly improves weight loss outcomes and contributes to the improvement of cardiovascular and metabolic parameters. Obiara 120 is generally well tolerated, with gastrointestinal side effects such as oily spotting, flatulence, and fecal urgency being the most common, typically related to dietary fat intake. Patients are advised to adhere to a nutritionally balanced, reduced-fat diet to minimize adverse effects and ensure adequate intake of fat-soluble vitamins, which may require supplementation during prolonged therapy.